BioCentury
ARTICLE | Management Tracks

Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore

February 22, 2021 1:01 PM UTC

Israeli diagnostics company Novellus has tapped former Immunomedics executive Usama Malik as its new CEO as it moves to the U.S. and rebrands as a precision therapeutics company, the newly named Fore Biotherapeutics.

In its new incarnation, Fore will develop in-licensed, clinical small molecules for targeted oncology applications. The first will be BRAF inhibitor PLX-8394, which is in a Phase I dose-finding trial; a Phase II study is to follow this year...

BCIQ Company Profiles

Fore Biotherapeutics Inc.